PMID- 21900389
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20220408
IS  - 1557-3265 (Electronic)
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 17
IP  - 22
DP  - 2011 Nov 15
TI  - Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
PG  - 6958-62
LID - 10.1158/1078-0432.CCR-11-1595 [doi]
AB  - Ipilimumab (MDX-010, Yervoy; Bristol-Myers Squibb), a fully human monoclonal 
      antibody against CTL antigen 4 (CTLA-4), was recently approved by the U.S. Food 
      and Drug Administration (FDA) for the treatment of metastatic melanoma. In both 
      early- and late-phase trials, ipilimumab has shown consistent activity against 
      melanoma. For example, in a randomized phase III trial that enrolled patients 
      with previously treated metastatic disease, ipilimumab, with or without a peptide 
      vaccine, improved overall survival: Median overall survival was 10.1 and 10.0 
      months in the ipilimumab and ipilimumab plus vaccine arms, respectively, versus 
      6.4 months in the vaccine-alone group (hazard ratio, 0.68; P </= 0.003). Serious 
      (grade 3-5) immune-related adverse events occurred in 10% to 15% of patients. 
      Thus, although it provides a clear survival benefit, ipilimumab administration 
      requires careful patient monitoring and sometimes necessitates treatment with 
      immune-suppressive therapy. Here, we review the mechanism of action, preclinical 
      data, and multiple clinical trials that led to FDA approval of ipilimumab for 
      metastatic melanoma.
FAU - Lipson, Evan J
AU  - Lipson EJ
AD  - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University 
      School of Medicine, Baltimore, Maryland 21231, USA.
FAU - Drake, Charles G
AU  - Drake CG
LA  - eng
GR  - P50 CA058236/CA/NCI NIH HHS/United States
GR  - R01 CA127153/CA/NCI NIH HHS/United States
GR  - 1P50CA58236-15/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110907
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CTLA-4 Antigen)
RN  - 0 (Ipilimumab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects/*pharmacology/*therapeutic use
MH  - Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use
MH  - CTLA-4 Antigen/drug effects/immunology
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Ipilimumab
MH  - Melanoma/*drug therapy/secondary
MH  - Skin Neoplasms/*drug therapy/pathology
PMC - PMC3575079
MID - NIHMS438132
EDAT- 2011/09/09 06:00
MHDA- 2012/03/27 06:00
PMCR- 2013/02/18
CRDT- 2011/09/09 06:00
PHST- 2011/09/09 06:00 [entrez]
PHST- 2011/09/09 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
PHST- 2013/02/18 00:00 [pmc-release]
AID - 1078-0432.CCR-11-1595 [pii]
AID - 10.1158/1078-0432.CCR-11-1595 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. 
      Epub 2011 Sep 7.